Can statin treatment cut cardiovascular risk in HIV-infected patients?

[From MedicalXpress, Oct 27, 2014] A nationwide study based at Massachusetts General Hospital (MGH) will investigate, for the first time, whether treatment with a statin drug can reduce the elevated risk of cardiovascular disease in individuals infected with the human immunodeficiency virus (HIV). The REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial is funded by the National Heart, Lung, and Blood Institute (NHLBI) and will be conducted in collaboration with the AIDS Clinical Trials Group, funded by the National Institute of Allergy and Infectious Diseases (NIAID). MGH will receive more than $39 million in direct support of the trial. Kowa Pharmaceuticals America, Inc, will provide the study drug and additional study funds.

For the full article, click here.

Leave a Comment

Scroll to Top